GlassScriptPhysician profile
Jacqueline Bannister
NPI 1194089227
$12,968.11
in general payments reported to CMS, 2019-2025
25 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,044 · 2022: $1,883 · 2023: $2,668 · 2024: $4,213 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,013 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,013.09 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,993.30 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,726.33 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $1,185.61 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $1,151.32 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $1,084.21 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Janssen Pharmaceuticals, INC | $789.69 | 2021-2025 | Invega Trinza, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $695.12 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $638.67 | 2021-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $613.71 | 2021-2025 | Ingrezza |
| Corium, LLC | $555.88 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $455.81 | 2023-2025 | Auvelity, Sunosi |
| Almatica Pharma LLC | $362.26 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Lundbeck LLC | $346.85 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $343.42 | 2023-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $238.96 | 2024-2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $167.55 | 2024 | |
| Idorsia Pharmaceuticals US INC | $142.29 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $120.48 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $109.90 | 2021 | |
| Collegium Pharmaceutical, INC. | $53.56 | 2025 | Jornay Pm |
| Indivior INC. | $53.09 | 2022-2024 | Perseris |
| Tris Pharma INC | $48.19 | 2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $37.95 | 2021 | |
| Adlon Therapeutics L.P. | $28.08 | 2021 | |
| Boston Scientific Corporation | $25.88 | 2025 | Ams 700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Bannister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.